OR2A1 and diffuse large B-cell lymphoma: OR2A1‐AS1 expression was considerably reduced in DLBCL patients, reduced OR2A1‐AS1 expression was linked to a shorter overall survival (OS) and progression‐free survival (PFS) in DLBCL patients, especially those with the germinal center B‐cell‐like subtype (GCB).